Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Lenvatinib plus either pembrolizumab or everolimus was compared with sunitinib as first-line therapy for advanced renal cell cancer. Progression-free survival was significantly longer with lenvatinib plus pembrolizumab than with sunitinib.
— NEJM (@NEJM) February 13, 2021